Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ISAL 2017 View overview page

2:48
Safety and efficacy of venetoclax plus LDAC in treatment-naive AML patients aged ≥ 65 years
Andrew Wei • 19 Feb 2017
4:20
Developments in therapies for AML – chemotherapy, targeted therapy and immunotherapy
Hagop Kantarjian • 19 Feb 2017
2:18
The utility of measurable residual disease (MRD) assessment in acute myeloid leukemia (AML)
Gert J. Ossenkoppele • 19 Feb 2017
1:36
The history of collaboration in acute promyelocytic leukemia (APL) research
Francesco Lo-Coco • 19 Feb 2017
4:57
The molecular heterogeneity of acute myeloid leukemia (AML) – new data and implications
Bob Löwenberg • 19 Feb 2017
2:30
Understanding the complexity of acute myeloid leukemia (AML)
Andrew Wei • 19 Feb 2017
2:02
Progress in acute myeloid leukemia treatment – collaborating to develop targeted therapies
Wolfgang Hiddemann • 20 Feb 2017
1:33
Highlights from the International Symposium on Acute Leukemias (ISAL) 2017 in Munich
Wolfgang Hiddemann • 20 Feb 2017
1:44
BiTES for the treatment of acute myeloid leukemia (AML) – results with AMG 330 in ex vivo study
Marion Subklewe • 19 Feb 2017
1:22
The importance of finding strategies to prevent relapse of acute myeloid leukemia (AML)
Kristoffer Hellstrand • 19 Feb 2017
1:21
A new era of treatment for elderly acute myeloid leukemia (AML) patients?
Hagop Kantarjian • 19 Feb 2017
1:42
Developments in prognostic factors of acute myeloid leukemia (AML)
Gert J. Ossenkoppele • 19 Feb 2017
1:31
Exploring combinatorial approaches in acute myeloid leukemia (AML) treatment
Francesco Lo-Coco • 19 Feb 2017
3:15
Perspectives in AML treatment: targeting apoptosis without chemotherapy by using BH3-mimetics
Andrew Wei • 19 Feb 2017
1:32
Developing targeted therapies to combine with venetoclax in acute myeloid leukemia (AML)
Marina Konopleva • 19 Feb 2017
1:17
Remission maintenance with histamine dihydrochloride (HDC)/IL-2 therapy in AML
Kristoffer Hellstrand • 19 Feb 2017
The content of VJHemOnc is intended for healthcare professionals